Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 2/20 | 0.32 |
| ▸ | ARG2 | P78540 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL21295559 | 0.98 | NPSR1 (0.48) | NPSR1APPPAOXALDH1A1LMNA | |
| SCHEMBL15345862 | 0.93 | NPSR1 (0.48) | NPSR1APPPAOXALDH1A1LMNA | |
| SCHEMBL2185541 | 0.93 | NPSR1 (0.44) | NPSR1APPPAOXALDH1A1LMNA | |
| Sulfuric Acid SCHEMBL29054619 | 0.91 | NPSR1 (0.52) | NPSR1APPPAOXALDH1A1LMNA | |
| SCHEMBL27938410 | 0.91 | NPSR1 (0.47) | NPSR1APPPAOXALDH1A1LMNA | |
| SCHEMBL17833359 | 0.89 | NPSR1 (0.42) | NPSR1APPPAOXLMNAPTGS1 | |
| SCHEMBL14686407 | 0.89 | NPSR1 (0.42) | NPSR1APPPAOXLMNAPTGS1 | |
| Eprodisate SCHEMBL23795566 | 0.85 | APP (0.46) | NPSR1APPPAOXALDH1A1LMNA | |
| SCHEMBL3117109 | 0.85 | NPSR1 (0.44) | NPSR1APPPAOXALDH1A1LMNA | |
| SCHEMBL16666053 | 0.85 | APP (0.50) | NPSR1APPLMNAPTGS1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2025743-B1 | Hard surface cleaning compostion | PROCTER & GAMBLE (US) | 2011-04-13 | — | — | EP | claimed |
| US-12491364-B2 | Monitoring of neuromodulation using biomarkers | MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY (IE) | 2025-12-09 | — | — | US | disclosed |
| EP-3348220-B1 | BIOMARKER SAMPLING IN THE CONTEXT OF NEUROMODULATION DEVICES AND ASSOCIATED SYSTEMS | MEDTRONIC ARDIAN LUXEMBOURG (LU) | 2024-10-23 | — | — | EP | disclosed |
| US-12121725-B2 | Biomarker sampling in the context of neuromodulation devices, systems, and methods | MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY (IE) | 2024-10-22 | — | — | US | disclosed |
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC (CA) | 2024-02-29 | — | — | US | disclosed |
| US-11779392-B2 | Methods and devices for localized disease treatment by ablation | MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY (IE) | 2023-10-10 | — | — | US | disclosed |
| US-20220296891-A1 | MONITORING OF NEUROMODULATION USING BIOMARKERS | MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY (IE) | 2022-09-22 | — | — | US | disclosed |
| US-11338140-B2 | Monitoring of neuromodulation using biomarkers | MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L. (LU) | 2022-05-24 | — | — | US | disclosed |
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-10473658-B2 | 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof | VISEN MEDICAL, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-7253306-B2 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-07 | — | — | US | disclosed |
| US-7244764-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-07-17 | — | — | US | disclosed |
| US-7244764-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-07-17 | — | — | US | disclosed |
| US-20070052783-A1 | Ink for inkjet printing ink set for inkjet printing inkjet recording material and producing method for inkjet recording material and inkjet recording method | FUJIFILM CORPORATION (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060293370-A1 | Sulfonamide compounds and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006135860-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-1646659-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | Neurochem (International) Limited (CH) | 2006-04-19 | — | — | EP | disclosed |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-06-30 | — | — | US | disclosed |
| WO-2004113391-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | FABP7, PYGB, ATP6V1B2 | NPSR1 353/4885APP 1256/4885PAOX 1625/4885 |
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | NPSR1 391/4885APP 1/4885PAOX 1669/4885 |
| US-20060293370-A1 | Sulfonamide compounds and uses thereof | GHSR, GHRHR, SSTR2 | NPSR1 23/4885APP 2904/4885PAOX 1119/4885 |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | MPST, TTR, STS | NPSR1 1526/4885APP 86/4885PAOX 938/4885 |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | GHSR, GHRHR, SSTR2 | NPSR1 23/4885APP 2904/4885PAOX 1119/4885 |
| US-10473658-B2 | 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof | CPNE4, LIG4, S100A4 | NPSR1 1971/4885APP 1072/4885PAOX 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.